<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id><journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id><journal-title-group><journal-title>Anais Brasileiros de Dermatologia</journal-title></journal-title-group><issn pub-type="ppub">0365-0596</issn><issn pub-type="epub">1806-4841</issn><publisher><publisher-name>Sociedade Brasileira de Dermatologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23793205</article-id><article-id pub-id-type="pmc">3754369</article-id><article-id pub-id-type="doi">10.1590/abd1806-4841.20131800</article-id><article-categories><subj-group subj-group-type="heading"><subject>Investigation</subject></subj-group></article-categories><title-group><article-title>Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study<xref ref-type="other" rid="fn03">*</xref>
</article-title><trans-title-group xml:lang="pt"><trans-title>Tratamento de pitir&#x000ed;ase versicolor com aplica&#x000e7;&#x000e3;o t&#x000f3;pica do &#x000f3;leo essencial de Cymbopogon citratus (DC) Stapf - estudo terap&#x000ea;utico piloto</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Carmo</surname><given-names>Egberto Santos</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Fillipe de Oliveira</given-names></name><xref ref-type="aff" rid="aff02">
2</xref></contrib><contrib contrib-type="author"><name><surname>Cavalcante</surname><given-names>Neuza Maria</given-names></name><xref ref-type="aff" rid="aff03">
3</xref></contrib><contrib contrib-type="author"><name><surname>Gayoso</surname><given-names>Carla Wanderley</given-names></name><xref ref-type="aff" rid="aff04">
4</xref></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Edeltrudes de Oliveira</given-names></name><xref ref-type="aff" rid="aff05">5</xref></contrib></contrib-group><aff id="aff01"><label>1</label> PHD - Professor of Clinical Microbiology, Federal University of Campina Grande (UFCG) - Cuit&#x000e9; (PB), Brazil
</aff><aff id="aff02"><label>2</label> PHD - Professor of Biochemistry, Federal University of Campina Grande (UFCG) - Cuit&#x000e9; (PB), Brazil.
</aff><aff id="aff03"><label>3</label> MSc &#x02013; Pharmaceutical Laboratory of Mycology, University Hospital Lauro Wanderley, Federal University of Paraiba (UFPB) &#x02013; Jo&#x000e3;o Pessoa (PB), Brazil.
</aff><aff id="aff04"><label>4</label> PHD &#x02013; Professor of Dermatology, Federal University of Paraiba (UFPB) &#x02013; Jo&#x000e3;o Pessoa (PB), Brazil.
</aff><aff id="aff05"><label>5</label> PHD &#x02013; Professor of Clinical Mycology, Federal University of Paraiba (UFPB) &#x02013; Jo&#x000e3;o Pessoa (PB), Brazil.
</aff><author-notes><corresp id="c01">
MAILING ADDRESS: Egberto Santos Carmo, Olho D'&#x000e1;gua da Bica, s/n - Centro, 58175-000 - Cuit&#x000e9; - PB, E-mail: <email>egbertosantos@ufcg.edu.br</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2013</year></pub-date><volume>88</volume><issue>3</issue><fpage>381</fpage><lpage>385</lpage><history><date date-type="received"><day>07</day><month>4</month><year>2012</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9;2013 by Anais Brasileiros de Dermatologia</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p></license></permissions><abstract><sec><title>BACKGROUND</title><p> Pityriasis versicolor is a fungal infection caused by Malassezia spp. that has frequent relapses. 
</p></sec><sec><title>OBJECTIVES</title><p> The main objective of this research was to perform phase I and II clinical studies, using formulations containing essential oil of Cymbopogon citratus in patients with pityriasis versicolor. 
</p></sec><sec><title>METHODS</title><p> Phase I study included twenty volunteers to ascertain the safety of the formulations. In phase II, 47 volunteers randomly received essential oil formulations at 1.25 &#x003bc;L/mL concentration, for forty days. The shampoo should be applied three times a week and the cream twice a day. A control group in phase II, consisting of 29 volunteers, received the same formulations but with 2% ketoconazole as the active ingredient. 
</p></sec><sec><title>RESULTS</title><p> No significant adverse events were observed in volunteers during Phase I. In Phase II, 30 (63.83%) volunteers using essential oil and 18 (62.07%) using ketoconazole remained until the end of the study. We observed a predominance of lesions in disseminated form, with <italic>M. sympodialis</italic> detected as the predominant agent identified in cultures. After 40 days of treatment, the rate of mycological cure was 60% (p &#x0003c;0.05) for the group treated with essential oil of C. citratus and over 80% (p &#x0003c;0.05) for the group treated with ketoconazole formulations. 
</p></sec><sec><title>CONCLUSIONS</title><p> Notwithstanding the safety and antifungal effects observed in this study after application of formulations containing the essential oil of C. citratus, further studies with larger populations should be performed to confirm the actual potential of these formulations in the treatment of patients with Pityriasis versicolor.</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>FUNDAMENTOS</title><p> Pitir&#x000ed;ase versicolor &#x000e9; uma micose causada pela Malassezia spp., e que apresenta frequentes recidivas. 
</p></sec><sec><title>OBJETIVOS</title><p> Este trabalho objetivou realizar estudos cl&#x000ed;nicos de fase I e II, para essa patologia, com &#x000f3;leo essencial de Cymbopogon citratus. 
</p></sec><sec><title>M&#x000c9;TODOS</title><p> Na fase I, participaram vinte volunt&#x000e1;rios para averiguar a seguran&#x000e7;a das formula&#x000e7;&#x000f5;es. Na fase II, 47 volunt&#x000e1;rios receberam as formula&#x000e7;&#x000f5;es do &#x000f3;leo essencial a 1,25 &#x003bc;L/mL, as quais deveriam ser utilizadas por quarenta dias, sendo o xampu tr&#x000ea;s vezes por semana e o creme duas vezes ao dia. Um grupo controle na fase II, constitu&#x000ed;do por 29 volunt&#x000e1;rios recebeu as mesmas formula&#x000e7;&#x000f5;es, com cetoconazol a 2%. 
</p></sec><sec><title>RESULTADOS</title><p> Verificada a seguran&#x000e7;a das formula&#x000e7;&#x000f5;es com a finaliza&#x000e7;&#x000e3;o da fase I, onde nenhuma rea&#x000e7;&#x000e3;o adversa significativa foi observada nos indiv&#x000ed;duos sadios, conduziu-se a fase II. Nesta segunda fase, 30 (63,83%) volunt&#x000e1;rios utilizando &#x000f3;leo essencial e 18 (62,07%) cetoconazol permaneceram at&#x000e9; o final do estudo. Observaram-se nos pacientes com pitir&#x000ed;ase versicolor predom&#x000ed;nio de les&#x000f5;es na forma disseminada e M. sympodialis foi o agente predominante identificado em cultura. Ap&#x000f3;s 40 dias de tratamento, obteve-se um percentual de cura micol&#x000f3;gica de 60% (p &#x0003c; 0,05) para o grupo tratado com &#x000f3;leo essencial de C. citratus e superior a 80% (p &#x0003c; 0,05) para o grupo tratado com cetoconazol. 
</p></sec><sec><title>CONCLUS&#x000d5;ES</title><p> Apesar da seguran&#x000e7;a e efeito antif&#x000fa;ngico observados ap&#x000f3;s aplica&#x000e7;&#x000e3;o das formula&#x000e7;&#x000f5;es contendo &#x000f3;leo essencial de C. citratus, outros estudos com maior n&#x000fa;mero de portadores de pitir&#x000ed;ase versicolor precisam ser realizados para confirmar o real potencial destas formula&#x000e7;&#x000f5;es.</p></sec></trans-abstract><kwd-group><kwd>Antifungal agents</kwd><kwd>Infection</kwd><kwd>Malassezia</kwd><kwd>Mycoses</kwd><kwd>Tinea versicolor</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Pityriasis versicolor or Tinea versicolor is a superficial mycosis caused by yeasts of the genus <italic>Malassezia</italic> spp., prevalent in tropical countries and especially affecting individuals with diminished immunity status. It is a pigmentation disorder clinically characterized by the presence of macular lesions, initially perifollicular with fine scaling, variable color spanning from white to brown and occasionally becoming erythematous.<sup><xref ref-type="bibr" rid="B01">1</xref>-<xref ref-type="bibr" rid="B03">3</xref></sup>
</p><p>The treatment of this fungal infection varies depending on the severity of the lesions, usually including topical or systemic imidazole derivatives. However, the emergence of fungal strains resistant to the available antifungal agents on the market and the frequent bouts of recurrence of pityriasis versicolor in patients, demonstrate that the development of new antifungal agents is a necessary strategy to overcome problems encountered in treating this disease.<sup><xref ref-type="bibr" rid="B04">4</xref>-<xref ref-type="bibr" rid="B05">5</xref></sup>
</p><p>Several studies have reported the antimicrobial activity of the essential oil of <italic>Cymbopogon citratus</italic> (DC) Stapf against different Gram positive and Gram negative pathogenic bacteria, yeasts and filamentous fungi.<sup><xref ref-type="bibr" rid="B06">6</xref>-<xref ref-type="bibr" rid="B08">8</xref></sup> Some authors attribute the oil's antimicrobial properties to the presence of citral in its composition.<sup><xref ref-type="bibr" rid="B09">9</xref></sup> Investigations on this oil's activity over the genus <italic>Malassezia</italic> found that the growth of 100% strains was inhibited at 1.25 &#x003bc;L/mL concentration by a mechanism which certainly involved the essential oil-ergosterol interaction with the fungal membrane.<sup><xref ref-type="bibr" rid="B10">10</xref></sup>
</p><p>In addition to the proven antifungal activity of the essential oil of <italic>Cymbopogon citratus</italic>, other preclinical <italic>in vitro</italic> and <italic>in vivo</italic> studies on toxicity confirmed the safety of this product at low concentations.<sup><xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B14">14</xref></sup>
</p><p>Based on the aforementioned preclinical studies that confirmed the antifungal activity and safety of this oil, we conducted phase I and II clinical studies with two pharmaceutical formulations containing essential oil of <italic>C. citratus</italic> in the forms of shampoo and cream.</p></sec><sec sec-type="materials|methods"><title>MATERIAL AND METHODS</title><sec><title>Population</title><p>The study included 96 volunteers who attended the dermatology outpatient clinic in the Lauro Wanderley University Hospital at the Federal University of Paraiba between January 2010 and January 2011. Of this total, 20 volunteers participated in the clinical phase I study and 76 participated in the clinical phase II study.</p><p>At the end of Phase I, designed to assess the safety of the shampoo and cream formulations containing essential oil of <italic>C. citratus,</italic> a randomized, comparative phase II study with patients clinically diagnosed with Tinea versicolor was initiated in the aforementioned outpatient clinic.</p><p>Mycological diagnosis of individuals with pityriasis versicolor was confirmed by direct examination with addition of potassium hydroxide (KOH) at 20% and permanent Quink Ink (Parker) at 2:1 and culture in Mycosel Agar supplemented with ox bile and olive oil.<sup><xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B16">16</xref></sup> For identification of <italic>Malassezia</italic> species we followed the protocol proposed by Erchiga, Palomo and Moyano (2008). Pregnant women, immunosuppressed patients or those using antifungal drugs in the last 30 days were excluded from the survey.</p></sec><sec><title>Experimental Protocol</title><p>Patients were instructed to use both formulations: a shampoo and a cream containing the essential oil of <italic>C. citratus</italic> at 1.25 &#x003bc;L/mL concentration. The shampoo should be applied three times a week and the cream twice a day, both for forty days. Patients were instructed to apply the shampoo on the scalp in the morning and evening after bathing, leaving it to act for five minutes before rinsing and applying the cream at the lesions sites.</p><p>In Phase II there was a control group, comprised of 29 volunteers who used the same formulations, but containing 2% ketoconazole as the active constituent, following the same posology and treatment time frame.</p><p>At the end of the 40-day period, patients returned to the dermatology clinic and mycology laboratory at the hospital for evaluation of therapeutic response by direct examination and culture of lesions. Patients who agreed to participate in the study signed an informed consent form, as provided in the Regulatory Guidelines and Standards for Research involving human beings, Resolutions 196/96 and 251/97 National Health Council. This research was approved by the Ethics Committee in Human Research of the CCS/UFPB, protocol No. 0037.</p></sec><sec><title>Safety and tolerability</title><p>In both phases groups were evaluated regarding local and systemic toxicological manifestations, especially: stinging, swelling, redness, itching or other adverse reactions to any of the formulations.</p></sec><sec><title>Statistical Analyses</title><p>Nominal variables such as: sex, itching, skin color, location, color and type of lesion, and <italic>Malassezia</italic> species were analyzed using the chi-square test, while the continuous variable "age" was analyzed by unpaired t-test (student). To examine the efficacy of the two treated groups (before and after treatment) and compare the healing power of the products (i.e the proportion of patients with mycological cure) we used the Fischer test. Tests were performed using GraphPad Prism(c) 5.00 (GraphPad Software, San Diego California, USA). Differences were considered statistically significant when p &#x0003c; 0.05.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Phase I</title><p>The average age of the 20 volunteers who participated in phase I was 25-37 years and 11 (55%) of them were males. The volunteers showed good acceptance of the formulations and reported no adverse reactions while using them or afterwards. A volunteer (5%) when asked about possible symptoms reported a burning sensation in the scalp on the first day of using the shampoo containing essential oil of <italic>C. citratus</italic>.</p></sec><sec><title>Phase II</title><p>After the safety of formulations was verified in phase I, we proceeded with phase II. At this time, thirty volunteers that used products containing essential oil of <italic>C. citratus</italic> and eighteen using 2% ketoconazole formulations completed the treatment, reaching a 36.17% non-adherence rate to the first group and 37.93% for the second. The reasons for failure in the assessment protocol were several: lack of trust in the treatment; fail to return to the service of dermatology or mycology laboratory and patients not found for follow-up.</p><p>No statistically significant difference was observed for demographic data of patients evaluated in phase II (
<xref ref-type="table" rid="t01">Table 1</xref>). The species <italic>M. sympodialis</italic> was the predominant pathogen identified by culture, regardless of the treated group.</p><p>After the treatment period, there was a statistically significant reduction in the number of patients with pityriasis versicolor in both groups (<xref ref-type="fig" rid="g01">Graph 1</xref>). Although data on mycological cure have pointed differences in results between groups treated with oil and ketoconazole, both groups showed relevant therapeutic response confirmed respectively by mycological cure equal or superior to 60% (<xref ref-type="fig" rid="g02">Graph 2</xref>).</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical characteristics of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"><bold>Patients</bold></td><td rowspan="1" colspan="1"><bold>Essential oil (n=30)</bold></td><td rowspan="1" colspan="1"><bold>Ketoconazole (n=18)</bold></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (mean, [range])</td><td rowspan="1" colspan="1">14-65 (32.8 years)</td><td rowspan="1" colspan="1">13-56 (33.5 years)</td></tr><tr><td rowspan="1" colspan="1">Gender (M/F)</td><td rowspan="1" colspan="1">10 (33.3%)/ 20 (66.7%)</td><td rowspan="1" colspan="1">10 (55.5%)/ 8 (44.4%)</td></tr><tr><td colspan="3" rowspan="1">
</td></tr><tr><td colspan="3" rowspan="1"><bold>Skin color</bold></td></tr><tr><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">16 (53.3%)</td><td rowspan="1" colspan="1">6 (33.3%)</td></tr><tr><td rowspan="1" colspan="1">Brown</td><td rowspan="1" colspan="1">12 (40.0%)</td><td rowspan="1" colspan="1">6 (33.3%)</td></tr><tr><td rowspan="1" colspan="1">Black</td><td rowspan="1" colspan="1">2 (6.7%)</td><td rowspan="1" colspan="1">6 (33.3%)</td></tr><tr><td colspan="3" rowspan="1">
</td></tr><tr><td colspan="3" rowspan="1"><bold>Site of the lesion</bold></td></tr><tr><td rowspan="1" colspan="1">Face</td><td rowspan="1" colspan="1">1 (3.3%)</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Front torso</td><td rowspan="1" colspan="1">4 (13.3%)</td><td rowspan="1" colspan="1">1 (5.5%)</td></tr><tr><td rowspan="1" colspan="1">Back torso</td><td rowspan="1" colspan="1">4 (13.3%)</td><td rowspan="1" colspan="1">3 (16.7%)</td></tr><tr><td rowspan="1" colspan="1">Upper limbs</td><td rowspan="1" colspan="1">7 (23.3%)</td><td rowspan="1" colspan="1">4 (22.%)</td></tr><tr><td rowspan="1" colspan="1">Lower limbs</td><td rowspan="1" colspan="1">1 (3.3%)</td><td rowspan="1" colspan="1">1 (5.5%)</td></tr><tr><td rowspan="1" colspan="1">Disseminated</td><td rowspan="1" colspan="1">13 (43.4%)</td><td rowspan="1" colspan="1">9 (50%)</td></tr><tr><td rowspan="1" colspan="1">Itch</td><td rowspan="1" colspan="1">12 (40.0%)</td><td rowspan="1" colspan="1">8 (44.4%)</td></tr><tr><td colspan="3" rowspan="1">
</td></tr><tr><td colspan="3" rowspan="1"><bold>Color of the lesion</bold></td></tr><tr><td rowspan="1" colspan="1">Hypochromic</td><td rowspan="1" colspan="1">25 (83.3%)</td><td rowspan="1" colspan="1">14 (77.8%)</td></tr><tr><td rowspan="1" colspan="1">Hyperchromic</td><td rowspan="1" colspan="1">4 (13.3%)</td><td rowspan="1" colspan="1">3 (16.7%)</td></tr><tr><td rowspan="1" colspan="1">Erythematous</td><td rowspan="1" colspan="1">1 (3.3%)</td><td rowspan="1" colspan="1">1 (5.5%)</td></tr><tr><td colspan="3" rowspan="1">
</td></tr><tr><td colspan="3" rowspan="1"><bold>Type of lesion</bold></td></tr><tr><td rowspan="1" colspan="1">Pityrosporum</td><td rowspan="1" colspan="1">6 (20.0%)</td><td rowspan="1" colspan="1">3 (16.7%)</td></tr><tr><td rowspan="1" colspan="1">Plates</td><td rowspan="1" colspan="1">23 (76.7%)</td><td rowspan="1" colspan="1">15 (83.3%)</td></tr><tr><td rowspan="1" colspan="1">Both</td><td rowspan="1" colspan="1">1 (3.3%)</td><td rowspan="1" colspan="1">-</td></tr><tr><td colspan="3" rowspan="1">
</td></tr><tr><td colspan="3" rowspan="1"><bold>Malassezia species</bold></td></tr><tr><td rowspan="1" colspan="1">M. sympodialis</td><td rowspan="1" colspan="1">10 (33.3%)</td><td rowspan="1" colspan="1">6 (33.3%)</td></tr><tr><td rowspan="1" colspan="1">M. furfur</td><td rowspan="1" colspan="1">8 (26.7%)</td><td rowspan="1" colspan="1">2 (11.1%)</td></tr><tr><td rowspan="1" colspan="1">M. obtusa</td><td rowspan="1" colspan="1">1 (3.3%)</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">M. globosa</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1 (5.5%)</td></tr><tr><td rowspan="1" colspan="1">M. sloofiae</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1 (5.5%)</td></tr><tr><td rowspan="1" colspan="1">Malassezia spp</td><td rowspan="1" colspan="1">11 (36.7%)</td><td rowspan="1" colspan="1">8 (44.4%)</td></tr></tbody></table><table-wrap-foot><fn id="tfn01"><p>- : Not detected</p></fn></table-wrap-foot></table-wrap><fig id="g01" orientation="portrait" position="float"><label>GRAPH 1</label><caption><p>Patients with mycosis before (day 1) and after treatment
(41 days) with cream and shampoo with essential oil of C.
citratus or Ketoconazole * p &#x0003c;0.05 (Fischer's test)</p></caption><graphic xlink:href="abd-88-0381-g01"/></fig><fig id="g02" orientation="portrait" position="float"><label>GRAPH 2</label><caption><p>Percentage of patients with mycological cure after treatment
with cream and shampoo containing essential oil of C. citratus
or ketoconazole. * p &#x0003c;0.05 (Fischer's test)</p></caption><graphic xlink:href="abd-88-0381-g02"/></fig></sec><sec><title>Safety and tolerability</title><p>From the standpoint of safety and tolerability, a voluntary group with 2% ketoconazole reported headache during use of this formulation, which did not discouraged him from continuing treatment and returning to the dermatology service for reassessment.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The formulations were well tolerated by the group on phase I. However a volunteer (5%) cited a burning sensation on the scalp on the first day of shampoo application. It might not be related to the formulation containing the essential oil of <italic>C. citratus itself</italic>, but to other variables such as the manner it was applied to the scalp.</p><p>The demographic data in this study are in agreement with several other studies in Brazil and worldwide. Pityriasis versicolor is a cosmopolitan disease that affects infants to elders, mostly aged between 15 and 30 years.<sup><xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B18">18</xref></sup> Patients with pityriasis versicolor usually have multiple lesions on the trunk, especially on the back, interspersed with normal skin. The neck and proximal upper extremities are also frequently affected. On the face, lesions are more common in children than in adults.<sup><xref ref-type="bibr" rid="B01">1</xref>,<xref ref-type="bibr" rid="B18">18</xref></sup> The following frequencies of lesions were observed through a study performed in Manaus (Brazil): widespread (31.50%), trunk (20.65%), upper limbs (13.75%), lower limbs (9.50%), face (8.85%).<sup><xref ref-type="bibr" rid="B19">19</xref></sup>
</p><p>Regarding the etiologic agent, this study showed a prevalence of <italic>M. sympodialias</italic> and <italic>M. furfur</italic>. These agents were among the most commonly isolated in other studies conducted in Goiania (Brazil) and countries like Spain and Indonesia.<sup><xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref></sup>
</p><p>The adherence was not a limiting factor for this research, since better results could have been perceived if many patients had not abandoned the treatment. Other phase II clinical studies for treatment of fungal infections, diabetes mellitus and fibromyalgia have observed similar adherence rates, ranging between 26-50%.<sup><xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B25">25</xref></sup>
</p><p>The mycological cure rate for patients treated with essential oil of <italic>C. citratus,</italic> reaffirms the antifungal potential of this oil on <italic>Malassezia</italic> yeasts observed in preclinical trials, as well as the safety of formulations in the applied concentration (1.25 &#x003bc;L/mL). However, there was a discrepancy in percentage of the etiological agent's sensitivity between <italic>in vitro</italic> and <italic>in vivo</italic> studies, a fact previously observed in similar studies.<sup><xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B27">27</xref></sup>
</p><p>Research on medicinal plants, especially on essential oils, are promising once such substances have markedly less side effects, low cost and increased security for population, when compared with antifungal agents available in the market, as the ketoconazole and amphotericin B.<sup><xref ref-type="bibr" rid="B06">6</xref>,<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B29">29</xref></sup>
</p><p>The products containing the essential oil of <italic>C. citratus</italic> used in this study, certainly by the low percentage in the formulation, showed an interesting cost/benefit, since their values were compatible with the formulations containing ketoconazole.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Results of this study indicate good prospects for clinical application of essential oil of <italic>C. citratus</italic> for treatment of Tinea versicolor, due to security and biological effects observed <italic>in vivo</italic> by mycological cure the group treated with the essential oil of <italic>C. citratus</italic>. However, it is interesting to conduct further studies with a large number of patients with pityriasis versicolor in order to verify the actual potential observed in this study.</p></sec></body><back><ack><p>We thank all the patients who voluntarily participated in this research.</p></ack><fn-group><fn id="fn03" fn-type="other"><p>* Research performed at the Hospital Universit&#x000e1;rio Lauro Wanderley at Federal University of Para&#x000ed;ba (UFPB) - Jo&#x000e3;o Pessoa (PB), Brazil.</p></fn><fn id="fn01" fn-type="conflict"><p>Conflict of interest: None</p></fn><fn id="fn02" fn-type="financial-disclosure"><p>Financial funding: None</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>JR</given-names></name><name><surname>Mazocco</surname><given-names>VT</given-names></name><name><surname>Steiner</surname><given-names>D</given-names></name></person-group><article-title>Pityriasis versicolor</article-title><source>An Bras Dermatol</source><year>2002</year><volume>77</volume><fpage>611</fpage><lpage>618</lpage></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erchiga</surname><given-names>VC</given-names></name><name><surname>Palomo</surname><given-names>MC</given-names></name><name><surname>Moyano</surname><given-names>EG</given-names></name></person-group><article-title xml:lang="es">Diagn&#x000f3;stico de laboratorio de las leveduras del g&#x000e9;nero Malassezia</article-title><source>Piel</source><year>2008</year><volume>23</volume><fpage>570</fpage><lpage>576</lpage></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Framil</surname><given-names>VMS</given-names></name><name><surname>Melhem</surname><given-names>MSC</given-names></name><name><surname>Szeszs</surname><given-names>MW</given-names></name><name><surname>Corneta</surname><given-names>ES</given-names></name><name><surname>Zaitz</surname><given-names>C</given-names></name></person-group><article-title>Pityriasis versicolor circinata: isolation of Malassezia sympodialis - Case report</article-title><source>An Bras Dermatol</source><year>2010</year><volume>85</volume><fpage>227</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">20520940</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odds</surname><given-names>FC</given-names></name><name><surname>Brown</surname><given-names>AJP</given-names></name><name><surname>Gow</surname><given-names>NAR</given-names></name></person-group><article-title>Antifungal agents: mechanisms of acion</article-title><source>Trends Microbiol</source><year>2003</year><volume>11</volume><fpage>272</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">12823944</pub-id></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber&#x000e1;n</surname><given-names>J</given-names></name><name><surname>Mensa</surname><given-names>J</given-names></name><name><surname>Fari&#x000f1;as</surname><given-names>C</given-names></name><name><surname>Llinares</surname><given-names>P</given-names></name><name><surname>Serrano</surname><given-names>R</given-names></name><name><surname>M&#x000e9;nendez</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Recommendations of antifungal treatment in patients with low grade inmunosuppression</article-title><source>Rev Esp Quimioter</source><year>2008</year><volume>21</volume><fpage>127</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">18509772</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimanga</surname><given-names>K</given-names></name><name><surname>Kambu</surname><given-names>K</given-names></name><name><surname>Tona</surname><given-names>L</given-names></name><name><surname>Apers</surname><given-names>S</given-names></name><name><surname>De Bruyne</surname><given-names>T</given-names></name><name><surname>Hermans</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Correlation between chemical composition and antibacterial activity of essential oils of some aromatic medicinal plants growing in the Democratic Republic of Congo</article-title><source>J Ethanopharmacol</source><year>2002</year><volume>79</volume><fpage>213</fpage><lpage>220</lpage></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irkin</surname><given-names>R</given-names></name><name><surname>Korukluoglu</surname><given-names>M</given-names></name></person-group><article-title>Effectiveness of Cymbopogon citratus L. essential oil to inhibit the growth of some filamentous fungi and yeasts</article-title><source>J Med Food</source><year>2009</year><volume>12</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">19298215</pub-id></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>MI</given-names></name><name><surname>Fomda</surname><given-names>BA</given-names></name><name><surname>Jaykumar</surname><given-names>E</given-names></name><name><surname>Bhat</surname><given-names>JA</given-names></name></person-group><article-title>Antibacterial activity of lemongrass (Cymbopogon citratus) oil against some selected pathogenic bacterias</article-title><source>Asian Pacific J Trop Med</source><year>2010</year><volume>3</volume><fpage>535</fpage><lpage>538</lpage></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuck</surname><given-names>VJA</given-names></name><name><surname>Fratini</surname><given-names>M</given-names></name><name><surname>Rauber</surname><given-names>CS</given-names></name><name><surname>Henriques</surname><given-names>A</given-names></name><name><surname>Schapoval</surname><given-names>EES</given-names></name></person-group><article-title>Evaluation of the antimicrobial activity of Cymbopogon citratus</article-title><source>Rev Bras Ci&#x000ea;nc Farm</source><year>2001</year><volume>37</volume><fpage>45</fpage><lpage>49</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Carmo</surname><given-names>ES</given-names></name></person-group><source xml:lang="pt">Ensaios pr&#x000e9;-cl&#x000ed;nicos e cl&#x000ed;nicos com &#x000f3;leo essencial de Cymbopogon citratus (DC) Stapf. para tratamento de pitir&#x000ed;ase versicolor</source><publisher-loc>Jo&#x000e3;o Pessoa, PB</publisher-loc><publisher-name>Universidade Federal da Paraiba</publisher-name><year>2011</year></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>AK</given-names></name><name><surname>Kishore</surname><given-names>N</given-names></name><name><surname>Dubey</surname><given-names>NK</given-names></name><name><surname>Chansouria</surname><given-names>JPN</given-names></name></person-group><article-title>An evaluation of the toxicity of the oils of Cymbopogon citratus and Citrus medica in rats</article-title><source>Phytother Res</source><year>1992</year><volume>6</volume><fpage>279</fpage><lpage>281</lpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fandohan</surname><given-names>P</given-names></name><name><surname>Gnonlonfin</surname><given-names>B</given-names></name><name><surname>Laleye</surname><given-names>A</given-names></name><name><surname>Gbenou</surname><given-names>JD</given-names></name><name><surname>Darboux</surname><given-names>R</given-names></name><name><surname>Moudachirou</surname><given-names>M</given-names></name></person-group><article-title>Toxicity and gastric tolerance of essential oils from Cymbopogon citratus, Ocimum gratissimum and Ocimum basilicum in Wistar rats</article-title><source>Food Chem Toxicol</source><year>2008</year><volume>46</volume><fpage>2493</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">18511170</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koffi</surname><given-names>K</given-names></name><name><surname>Komla</surname><given-names>S</given-names></name><name><surname>Catherine</surname><given-names>G</given-names></name><name><surname>Christine</surname><given-names>R</given-names></name><name><surname>Jean-Pierre</surname><given-names>C</given-names></name><name><surname>Laurence</surname><given-names>N</given-names></name></person-group><article-title>In vitro cytotoxic activity of Cymbopogon citratus L. and Cymbopogon nardus L. essential oils from Togo</article-title><source>Bangladesh J Pharmacol</source><year>2009</year><volume>4</volume><fpage>29</fpage><lpage>34</lpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidinotto</surname><given-names>LT</given-names></name><name><surname>Costa</surname><given-names>CA</given-names></name><name><surname>Salvadori</surname><given-names>DM</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Rodrigues</surname><given-names>MA</given-names></name><name><surname>Barbisan</surname><given-names>LF</given-names></name></person-group><article-title>Protective effects of lemongrass (Cymbopogon citratus STAPF) essential oil on DNA damage and carcinogenesis in female Balb/C mice</article-title><source>J Appl Toxicol</source><year>2010</year><pub-id pub-id-type="doi">10.1002/jat.1593</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Waili</surname><given-names>NS</given-names></name></person-group><article-title>An alternative treatment for pityriasis versicolor, tinea cruris, tinea corporis and tinea faciei with topical application of honey, olive oil and beeswax mixture: an open pilot study</article-title><source>Complem Therap Med</source><year>2004</year><volume>12</volume><fpage>45</fpage><lpage>47</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>LGA</given-names></name></person-group><source xml:lang="pt">Identifica&#x000e7;&#x000e3;o de esp&#x000e9;cies de Malassezia em pacientes com pitir&#x000ed;ase versicolor atendidos no ambulat&#x000f3;rio de dermatologia CAME-primavera em Jo&#x000e3;o Pessoa-PB</source><publisher-loc>Recife, PE</publisher-loc><publisher-name>Universidade Federal de Pernambuco</publisher-name><year>2004</year></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arenas</surname><given-names>R</given-names></name><name><surname>Isa</surname><given-names>RI</given-names></name><name><surname>Cruz</surname><given-names>AC</given-names></name></person-group><article-title xml:lang="pt">Pitiriasis versicolor en Santo Domingo, Rep&#x000fa;blica Dominicana. Datos morfol&#x000f3;gicos de Malassezia spp. in vivo en 100 casos</article-title><source>Rev Iberoam Micol</source><year>2001</year><volume>18</volume><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15482011</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintero</surname><given-names>MEA</given-names></name><name><surname>Perfetti</surname><given-names>DJ</given-names></name></person-group><article-title>Clinical-epidemiological aspects of pytiriasis versicolor (PV) in a fishing community of semiarid region from Falcon State, Venezuela</article-title><source>Rev Iberoam Micol</source><year>2004</year><volume>21</volume><fpage>191</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">15709799</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furtado</surname><given-names>MSS</given-names></name><name><surname>Cort&#x000ea;z</surname><given-names>ACA</given-names></name><name><surname>Ferreira</surname><given-names>JA</given-names></name></person-group><article-title>Pityriasis versicolor in Manaus, Amazonas, Brazil</article-title><source>An Bras Dermatol</source><year>1997</year><volume>72</volume><fpage>349</fpage><lpage>351</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aspiroz</surname><given-names>C</given-names></name><name><surname>Ara</surname><given-names>M</given-names></name><name><surname>Varea</surname><given-names>M</given-names></name><name><surname>Rezusta</surname><given-names>A</given-names></name><name><surname>Rubio</surname><given-names>C</given-names></name></person-group><article-title>Isolation of Malassezia globosa and M. sympodialis from patients with pityriasis versicolor in Spain</article-title><source>Mycopathologia</source><year>2002</year><volume>154</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">12171443</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>KC</given-names></name><name><surname>Araujo</surname><given-names>CR</given-names></name><name><surname>Soares</surname><given-names>AJ</given-names></name><name><surname>Lemos</surname><given-names>JA</given-names></name><name><surname>Hasimoto e Souza</surname><given-names>LK</given-names></name><name><surname>Silva</surname><given-names>MRR</given-names></name></person-group><article-title>Identification of Malassezia species in patients with pityriasis versicolor in Goi&#x000e2;nia-GO</article-title><source>Rev Soc Bras Med Trop</source><year>2006</year><volume>39</volume><fpage>582</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">17308710</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krisanty</surname><given-names>RIA</given-names></name><name><surname>Bramono</surname><given-names>K</given-names></name><name><surname>Wisnu</surname><given-names>IM</given-names></name></person-group><article-title>Identification of Malassezia species from pityriasis versicolor in Indonesia and its relationship with clinical characteristics</article-title><source>Mycoses</source><year>2008</year><volume>52</volume><fpage>257</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">18643886</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>PG</given-names></name><name><surname>Chetchotisakd</surname><given-names>P</given-names></name><name><surname>Larsen</surname><given-names>RA</given-names></name><name><surname>Manosuthi</surname><given-names>W</given-names></name><name><surname>Morris</surname><given-names>MI</given-names></name><name><surname>Anekthananon</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV-Associated Cryptococcal Meningitis</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><fpage>1775</fpage><lpage>1783</lpage><pub-id pub-id-type="pmid">19441980</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>AS</given-names></name></person-group><source xml:lang="pt">Efeito da farinha desengordurada do Sesamum indicum L. nos n&#x000ed;veis glic&#x000ea;micos e lip&#x000ed;dicos de diab&#x000e9;ticos tipo 2</source><publisher-loc>Jo&#x000e3;o Pessoa, PB</publisher-loc><publisher-name>Universidade Federal da Paraiba</publisher-name><year>2008</year></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>ASBC</given-names></name></person-group><source xml:lang="pt">Ensaio farmacol&#x000f3;gico clinico com extrato das ra&#x000ed;zes do Panax ginseng C.A. Meyer no tratamento da fibromialgia</source><publisher-loc>Jo&#x000e3;o Pessoa, PB</publisher-loc><publisher-name>Universidade Federal da Paraiba</publisher-name><year>2009</year></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>RG</given-names></name><name><surname>Hill</surname><given-names>RP</given-names></name></person-group><article-title>Comparison between In vitro radiosensitivity and in vivo radioresponse in murine tumor cell lines II: in vivo radioresponse following fractionated treatment and in vitro/in vivo correlations</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1990</year><volume>18</volume><fpage>331</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">2303364</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Tudela</surname><given-names>JL</given-names></name><name><surname>Alcazar-Fuoli</surname><given-names>L</given-names></name><name><surname>Cuesta</surname><given-names>I</given-names></name><name><surname>Alastruey-Izquierdo</surname><given-names>A</given-names></name><name><surname>Monzon</surname><given-names>A</given-names></name><name><surname>Mellado</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Clinical relevance of resistance to antifungals</article-title><source>Int J Antimicrobial Agents</source><year>2008</year><volume>32</volume><fpage>S111</fpage><lpage>S113</lpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>MCT</given-names></name><name><surname>Figueira</surname><given-names>GM</given-names></name><name><surname>Sartoratto</surname><given-names>A</given-names></name><name><surname>Rehder</surname><given-names>VL</given-names></name><name><surname>Delarmelina</surname><given-names>C</given-names></name></person-group><article-title>Anti-Candida activity of brasilian medicinal plants</article-title><source>J Ethnopharmacol</source><year>2005</year><volume>97</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">15707770</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>XP</given-names></name><name><surname>Maia</surname><given-names>GLA</given-names></name><name><surname>Almeida</surname><given-names>JRGS</given-names></name><name><surname>Pereira</surname><given-names>FO</given-names></name><name><surname>Lima</surname><given-names>EO</given-names></name></person-group><article-title>Antimicrobial activity of the essential oil of Sida cordifolia L</article-title><source>Braz J Pharmacogn</source><year>2006</year><volume>16</volume><fpage>S642</fpage><lpage>S644</lpage></element-citation></ref></ref-list></back></article>